Activity: Visiting an external institution › Visiting an external academic institution
Description
Lumiracoxib, is a non-steroidal anti-inflammatory drug that was previously used in the treatment of the arthritis. However, it was withdrawal from the market due to severe hepatotoxicity. The objective of this study is to develop Poly (δ-decalactone) based nanoemulsion to reduce hepatotoxicity of lumiracoxib. The purpose of this mobility is to conduct a toxicity study on a poly(δ-decalactone) based nanoemulsion of lumiracoxib in Prof. Stubelius’ lab at Chalmers University of Technology, Gothenburg, which has extensive expertise in this field. During this mobility action, we will utilize Chalmers’ state-of-the-art Luminex instrument to assess liver toxicity and to quantify several immune cytokines, enabling an in-depth understanding of the underlying mechanisms.